Press Releases

  • Jun. 14, 2017 biOasis CEO Dr. Mark Day Releases Details of Corporate Plans in Message to Shareholders

    VANCOUVER, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) Dr. Mark Day, chief executive officer, has issued a message to shareholders detailing plans for the advancement of the Transcend Platform and the company’s in-house programs. To the Shareholders of biOasis Technologies Inc.: As the new CEO of biOasis, I am delighted to send my first message… Read more »

  • Jun. 8, 2017 biOasis to Present at The Global Chinese Financial Forum – Shanghai Conference 2017

    VANCOUVER, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) announced today that Dr. Mark Day, the chief executive officer of biOasis, will present at the Global Chinese Financial Forum (GCFF) – Shanghai Conference 2017, in Shanghai, China, on June 22, 2017. biOasis Board Chairman, Rob Hutchison, will attend the conference with Dr. Day. Dr. Day’s presentation,… Read more »

  • Jun. 4, 2017 biOasis to Present at the 16th International Postgraduate Course on Lysosomal Storage Disorders

    VANCOUVER, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) announced today that Dr. Mark Day, chief executive officer, will present at the 16th International Postgraduate Course on Lysosomal Storage Disorders, in Nierstein (Mainz), Germany on June 07–10, 2017. Dr. Day’s presentation, “Improving the Probability of Success in CNS Drug Discovery and Development: A Case Study,” targets… Read more »

  • May. 16, 2017 biOasis Announces the Engagement of Mackie Research to Provide Market Making Services

    VANCOUVER, British Columbia–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) (the “Company”), is pleased to announce that, subject to regulatory approval, it has retained Mackie Research Capital Corporation (“Mackie Research”) to initiate its market making service to provide market making services to the Company in compliance with the policies and guidelines of the TSX Venture Exchange… Read more »

  • Apr. 24, 2017 BIOASIS ANNOUNCES GRANT OF STOCK OPTIONS AND RESTRICTED STOCK UNITS

    VANCOUVER, British Columbia–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) (the “Company”) is pleased to announce that pursuant to the terms of its stock option plan (the “Option Plan”) and restricted stock units plan (the “RSU Plan”), the Company has granted a total of 2,377,478 stock options and 225,000 Restricted Share Units (RSUs) to its officers,… Read more »

  • biOasis Announces Investor Relations Service Agreement

    VANCOUVER, British Columbia–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) (the “Company”) The Company announces that it has entered into an investor relations agreement (“Agreement”) with 551943 Alberta Ltd., operating as Colwell Capital Corp (“Colwell”), for a maximum term of twelve months commencing April 24, 2017. The Company will pay Colwell $4,000 per month and will… Read more »

  • biOasis Appoints Mark Day, Ph.D., as Chief Executive Officer and Director

    VANCOUVER, British Columbia–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) (the “Company”) has appointed Mark Day, Ph.D., as President and Chief Executive Officer of the Company, effective immediately. Dr. Day succeeds Mr. Rob Hutchison who will become Executive Chairman of the Board of Directors of the Company. Dr. Day will also serve on the biOasis Board… Read more »

  • Mar. 31, 2017 biOasis Announces Oversubscription of Financing

    VANCOUVER, British Columbia–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) (the “Company”) is pleased to announce that further to its press release dated March 20, 2017, the Company’s non-brokered private placement (the “Private Placement”), is currently over-subscribed. As a result, subject to regulatory approval, the size of the Private Placement has been increased from up to… Read more »

  • Mar. 20, 2017 biOasis Announces Non-Brokered Private Placement

    VANCOUVER, British Columbia–(Business Wire)– biOasis Technologies Inc. (TSX.V: BTI) (the “Company”) announces a nonbrokered private placement of up to 4,500,000 units at a price of $0.70 per unit of gross proceeds of up to $3,150,000 (the “Offering”). Each unit will consist of one common share and one-half common share purchase warrant. Each whole warrant entitles… Read more »

  • Jan. 23, 2017 biOasis Provides AGM Update – Expanding The biOasis Deal Flow Pipeline

    VANCOUVER, British Columbia–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on the delivery of therapeutic drugs across the blood-brain barrier (BBB), has provided a corporate update in advance of its Annual and Special Meeting of Shareholders to be held at 1780 – 400 Burrard Street, Vancouver, BC, on January 23, 2017… Read more »